Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Conatus Pharmaceuticals (CNAT) Competitors

Conatus Pharmaceuticals logo

CNAT vs. ASLN, CWBR, EVFM, ATXI, OGEN, PTPI, TRVN, PBLA, ATHX, and HEPA

Should you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Avenue Therapeutics (ATXI), Oragenics (OGEN), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Athersys (ATHX), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "medical" sector.

Conatus Pharmaceuticals vs. Its Competitors

Conatus Pharmaceuticals (NASDAQ:CNAT) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Conatus Pharmaceuticals' return on equity of -48.22% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Conatus Pharmaceuticals-52.42% -48.22% -39.32%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Conatus Pharmaceuticals Neutral
ASLAN Pharmaceuticals Neutral

15.2% of Conatus Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 11.3% of Conatus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Conatus Pharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Conatus Pharmaceuticals has higher revenue and earnings than ASLAN Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conatus Pharmaceuticals$21.72M0.00-$11.39MN/AN/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03

Summary

Conatus Pharmaceuticals beats ASLAN Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Conatus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

CNAT vs. The Competition

MetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$10K$780.12M$5.46B$8.92B
Dividend YieldN/A4.84%5.24%4.04%
P/E Ratio0.001.2927.0120.12
Price / Sales0.00230.51380.1493.34
Price / CashN/A23.4426.2128.59
Price / Book0.006.137.995.57
Net Income-$11.39M-$27.85M$3.16B$248.40M

Conatus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNAT
Conatus Pharmaceuticals
N/A$0.00
flat
N/A-99.9%$10K$21.72M0.0030
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12M-0.0330
CWBR
CohBar
N/A$0.41
flat
N/AN/A$1.19MN/A0.0010
EVFM
Evofem Biosciences
0.5922 of 5 stars
$0.01
+1.0%
N/A+3.1%$1.18M$11.39M-0.02120
ATXI
Avenue Therapeutics
2.1086 of 5 stars
$0.35
+74.4%
N/A-90.5%$1.11MN/A0.024Gap Up
OGEN
Oragenics
0.2165 of 5 stars
$1.55
-59.4%
N/A-94.9%$1.11M$40K-0.225Gap Down
High Trading Volume
PTPI
Petros Pharmaceuticals
0.6477 of 5 stars
$0.03
-2.4%
N/A-99.7%$1.02M$5.11M-0.0120Gap Up
TRVN
Trevena
1.6043 of 5 stars
$1.05
-5.4%
$5.00
+376.2%
-83.2%$1.01M$443K-0.0240Gap Down
High Trading Volume
PBLA
Panbela Therapeutics
0.0921 of 5 stars
$0.19
-18.2%
N/A-57.1%$921KN/A0.006Gap Down
High Trading Volume
ATHX
Athersys
N/AN/AN/AN/A$833K$146K0.0024
HEPA
Hepion Pharmaceuticals
0.6868 of 5 stars
$0.07
-14.9%
N/A-99.9%$744KN/A-0.0220Gap Down

Related Companies and Tools


This page (NASDAQ:CNAT) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners